Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026)
Gilead Sciences (GILD) reported Other Non-Current Assets of $4.6 billion for Q1 2026, up 17.64% on a YoY basis from $3.9 billion in Q1 2025, and down 6.01% quarter-over-quarter from $4.8 billion in Q4 2025.
Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Other Non-Current Assets for 18 years, with the latest figure at $4.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 17.64% year-over-year to $4.6 billion; the trailing twelve-month figure through Mar 2026 stood at $4.6 billion (up 17.64% YoY), and the FY2025 full-year result was $4.8 billion, up 28.55% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $4.6 billion, down from $4.8 billion in the prior quarter.
- The five-year high for Other Non-Current Assets was $5.5 billion in Q3 2024, with the low at $3.8 billion in Q4 2024.
- Historically, Other Non-Current Assets has averaged $4.7 billion across 5 years, with a median of $4.8 billion in 2022.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 30.81% — and 2025, when it fell 25.39%.
- Gilead Sciences' Other Non-Current Assets stood at $4.8 billion in 2022, then dropped by 0.17% to $4.8 billion in 2023, then dropped by 21.35% to $3.8 billion in 2024, then climbed by 28.55% to $4.8 billion in 2025, then declined by 6.01% to $4.6 billion in 2026.
- The last three Other Non-Current Assets figures came in at $4.6 billion (Q1 2026), $4.8 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.18 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.23 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 14.11 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 10.54 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 6.08 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 200.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.55 Bn |
| Dec 31, 2025 | 4.85 Bn |
| Sep 30, 2025 | 4.87 Bn |
| Jun 30, 2025 | 4.03 Bn |
| Mar 31, 2025 | 3.87 Bn |
| Dec 31, 2024 | 3.77 Bn |
| Sep 30, 2024 | 5.49 Bn |
| Jun 30, 2024 | 4.77 Bn |
| Mar 31, 2024 | 5.19 Bn |
| Dec 31, 2023 | 4.79 Bn |
| Sep 30, 2023 | 4.20 Bn |
| Jun 30, 2023 | 5.11 Bn |
| Mar 31, 2023 | 4.95 Bn |
| Dec 31, 2022 | 4.80 Bn |
| Sep 30, 2022 | 4.62 Bn |
| Jun 30, 2022 | 4.86 Bn |
| Mar 31, 2022 | 5.13 Bn |
| Dec 31, 2021 | 4.96 Bn |
| Sep 30, 2021 | 4.74 Bn |
| Jun 30, 2021 | 5.55 Bn |